12 completed. 12 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 12 |
| Phase 2 | 1 | Completed 1 |
Follow Dengue Fever: new trials by email Literature Review of Dengue Fever trials Research Report on Dengue Fever
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan TDV, Placebo - Dengue Fever | Phase 2 / Phase 3 | Completed | Takeda | 187 | 2025-01-31 | 2025-12-30 |
| The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever Ribavirin, Standard Treatment - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Khyber Medical University Peshawar | 284 | 2024-12-17 | 2025-06-26 |
| Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years 9vHPV Vaccine, Dengue Tetravalent Vaccine (TDV) - Dengue Fever | Phase 3 | Completed | Takeda | 614 | 2021-05-15 | 2024-02-07 |
| Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV), Placebo - Dengue Fever | Phase 3 | Completed | Takeda | 365 | 2019-11-12 | 2026-07-30 |
| Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults Tetravalent Dengue Vaccine (TDV) - Dengue Fever | Phase 3 | Completed | Takeda | 200 | 2019-03-28 | 2021-06-07 |
| Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue TAK-003, Placebo - Dengue Fever | Phase 3 | Completed | Takeda | 923 | 2018-02-12 | 2020-10-20 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® CYD Dengue Vaccine, Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant. - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 528 | 2016-12-01 | 2022-03-25 |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® CYD Dengue Vaccine, Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 480 | 2016-11-16 | 2022-03-25 |
| Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Live, attenuated, dengue serotype 1, 2, 3, 4 virus, Placebo: (NaCl) 0.9% solution - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 20869 | 2011-06-08 | 2022-03-21 |
| Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Live, attenuated, dengue serotype 1, 2, 3, 4 virus, Placebo: Sodium chloride (NaCl) 0.9% - Dengue, Dengue Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 10275 | 2011-06-03 | 2022-03-21 |
| Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus, Placebo: NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi | 250 | 2010-12-02 | 2022-03-25 |
| Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus, Placebo: NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 715 | 2010-10-05 | 2019-07-24 |
Dengue (12) · Severe Dengue (7) · Hemorrhage (1)
Arbovirus Infections (12) · Flaviviridae Infections (12) · Flavivirus Infections (12) · Hemorrhagic Fevers, Viral (12) · Infections (12) · Mosquito-Borne Diseases (12) · RNA Virus Infections (12) · Vector Borne Diseases (12) · Virus Diseases (12) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Dengue Vaccines (4) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · Ribavirin (1) · Sodium Chloride (1) · Solutions (1) · human papillomavirus vaccine, L1 type 16, 18 (1)
Sanofi Pasteur, a Sanofi Company (5) · Takeda (5) · Khyber Medical University Peshawar (1) · Sanofi (1)
Malaysia (3) · Mexico (3) · United States (3) · Thailand (2) · Australia (1) · Brazil (1) · Colombia (1) · Honduras (1) · Indonesia (1) · Japan (1) · Pakistan (1) · Philippines (1) · Puerto Rico (1) · Vietnam (1)
Akhtar Sherin, MBBS,MHR,PHD (1) · Noman Arif, MBBS (1) · Said Amin, MBBS,FCPS (1) · Sheraz Fazid, MBBS,MPH (1)
PMID 40099800, PMID 26214039, PMID 27007959, PMID 27418050, PMID 27459266, PMID 28871961, PMID 29300876, PMID 29897841, PMID 33212068, PMID 33822015, PMID 34003796, PMID 34219653, PMID 35659904, PMID 24135573, PMID 25018116, PMID 25365753, PMID 26279339, PMID 26614588, PMID 26639777, PMID 27414655, PMID 27532617, PMID 27601343, PMID 28590795, PMID 28598256, PMID 28968794, PMID 29408333, PMID 32040014, PMID 33992441, PMID 34250977, PMID 37846724, PMID 37884415, PMID 40749348, PMID 41058426, PMID 42480195
2019 (2), 2014 (1), 2023 (1)